Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 2c

Amneal Pharmaceuticals (: AMRX) reported Q4 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $610 million versus the consensus estimate of $579.84 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2023 revenue of $2.25-2.35 billion, versus the consensus of $2.31 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Goldman Sachs Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'